Nuvectis Pharma (NVCT) Liabilities and Shareholders Equity (2021 - 2026)

Nuvectis Pharma has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $25.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $25.4 million, down 15.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $119.7 million (up 41.89% YoY), and the FY2025 annual result was $31.7 million, up 70.41% from the prior year.
• Liabilities and Shareholders Equity came in at $25.4 million for Q1 2026 at Nuvectis Pharma, down from $31.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $35.6 million in Q3 2025 to a low of $14.2 million in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $20.4 million (2022), against an average of $22.6 million.
• Across the five-year window, Liabilities and Shareholders Equity jumped 206.52% in 2022 and fell 26.63% in 2024, its largest moves.
• Nuvectis Pharma's Liabilities and Shareholders Equity stood at $20.4 million in 2022, then slipped by 5.98% to $19.2 million in 2023, then declined by 3.01% to $18.6 million in 2024, then surged by 70.41% to $31.7 million in 2025, then dropped by 19.9% to $25.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $25.4 million (Q1 2026), $31.7 million (Q4 2025), and $35.6 million (Q3 2025), per Business Quant data.